Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ, 10 mg Peptide

Human Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ US$533.00 Excluding tax and shipping fees Limited stock Description About Human Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ The Human Amyloid beta (A4) protein HLA class I histocompatibi

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Human Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ

US$533.00

Excluding tax and shipping fees

Limited stock

Description

About Human Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ

The Human Amyloid beta (A4) protein HLA class I histocompatibility antigen, alpha chain F Peptide (IEDB: 99134) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Amyloid beta (A4) protein Peptide, H-DAEFRHDSGYEVHHQ-OH (Uniprot: P05067 aa: 172-186) from JPT is produced under strict quality control and quality management.

Human Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ - Specifications

Peptide sequence: H-DAEFRHDSGYEVHHQ-OH

Amount: 10 mg (10 x 1 mg)

Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)

Counterion: TFA

Delivery Format: Freeze-dried in plastic vial

Application(s): T-cell Immunity

Condition(s)/Topic(s): Alzheimer's disease

Standard Delivery Time: approx. 3 weeks

Your Custom or Scrambled Antigen Peptide!

Do you need a scrambled version of this antigen peptide?We can produce scrambled versions for all our antigen peptides and other peptide sequences. These scrambled peptide versions are cross-checked against the Uniprot database to ensure that the scrambled sequence does not correspond to any natural sequence. Have a look at Scrambled Antigen Peptides!

Are you interested in other antigen peptides?Choose sequence, amount and purity. We will assist you along the way: Custom Peptide Synthesis

JPT’s Antigen PeptidesFind your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.Not found what you are looking for? Take a look at our Custom Peptide Synthesis!

Benefits of JPT’s Antigen Peptides- All peptides are made in Germany- Bulk orders or custom peptide snythesis upon request- Synthesis protocols designed to avoid toxic contaminants and side products - Provision of freeze dried aliquots for enhanced stability - Proven track record for applications in clinical studies- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for Human Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ

References:Read References with Antigen Peptides

Documentation

Documentation for Human Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ

Protocol_PepMix.pdf

Amyloid-beta-precursor-protein-172-186-3.pdf

Properties

Properties of Human Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ

T-cell immunity

Antigen Peptides

Alzheimer's disease

Freeze-dried in glass vial, Freeze-dried in plastic vial

Human

Amyloid beta (A4) protein

Trial Grade: each peptide purified to > 90% (HPLC/MS)

No

Further Information to Human Amyloid-beta precursor protein 172-186, DAEFRHDSGYEVHHQ

Values

H-DAEFRHDSGYEVHHQ-OH

15mer peptide as TFA salt

Related Products

Related Products

Human Isoform APP751 of Amyloid-beta precursor protein 696-706, GSNKGAIIGLM

US$178.10

PepMix™ Human (Aquaporin-4)

US$646.10

Beta-Amyloid (1-40) HFIP treated

US$131.00

PepMix™ Pan-RSV Select

US$838.50

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What Drives MK-6240 Performance?

The performance of MK-6240 appears to be driven largely by differences in biologic binding characteristics, said Pascoal, who is also a behavioral neurologist at the University of Pittsburgh School of Medicine. “The main driver is biological affinity: MK-6240 binds tau tangles with roughly sixfold higher affinity than flortaucipir, as demonstrated in post-mortem tissue,” he explained. “This translates into a stronger signal-to-noise ratio in vivo, allowing detection of the sparse, early tangle deposits in medial temporal regions that flortaucipir tends to miss.” However, access to this newer tau PET tracer remains limited, he acknowledged. “Availability remains a real barrier,” Pascoal said. “MK-6240 is currently produced at a limited number of academic and trial-affiliated PET centers and is not yet approved as a routine clinical test.” The new agent received FDA Fast Track designation in 2025. The agency is expected to issue a decision on the manufacturer Lantheus’ new drug application expected in August, the company reported in a statement . The study provides evidence supporting sensitive approaches to tau detection, said Stephen Salloway, MD, director of Neurology and the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, who was not part of the research. “Early detection of AD pathology will be critical for testing new interventions to slow or prevent cognitive decline in individuals at risk for AD,” and MK-6240 is better at detecting early stages of tau pathology than the currently available tracer, Salloway told Medscape Medical News . However, he cautioned that broader clinical implementation will require additional work to standardize interpretation and staging. “Better molecular staging of AD is needed to improve diagnostic accuracy and to identify individuals most likely to benefit from treatment,” he said. “Nuclear medicine specialists, radiologists, and dementia experts need experience and training to interpret tau PET scans.” The study was funded by the National Institute on Aging. Disclosure information for study authors is available in the original study publication. Salloway reported having no relevant financial disclosures.

Source: www.medscape.com ↗
Research context

Read sources and limitations before applying a claim.

Research areas and applications of Beta-Amyloid (1-42), CAS: 107761-42-2

Neurodegeneration and Alzheimer’s research: Used to study how Amyloid beta 1-42 overproduction, impaired clearance, and rapid aggregation drive Alzheimer’s progression due to its high neurotoxicity and strong synaptic impact. Amyloid aggregation and plaque formation studies: Serves as a model for fast β-sheet nucleation, toxic oligomer formation, and the development of protofibrils and mature fibrils using NMR, AFM, and cryo-EM. Neurotoxicity, synaptic physiology, and neuronal function: Used to examine how beta amyloid oligomers disrupt synaptic signaling, alter calcium balance, impair plasticity, induce oxidative stress, and activate apoptosis that contributes to neuronal dysfunction. Anti-amyloid drug discovery and therapeutic development: Utilized to screen aggregation inhibitors, test Aβ-targeting monoclonal antibodies (e.g., beta amyloid 1-42 antibody), evaluate peptide-based therapeutics, and model compound effects that reduce amyloid burden. Biomarker development and diagnostics: Supports CSF and blood biomarker studies focused on decreased peptide levels and its ratio with Amyloid beta (1-40), both strongly linked to amyloid PET imaging and early Alzheimer’s diagnosis. APP processing and familial Alzheimer’s disease research: Used to analyze how APP, PSEN1, and PSEN2 mutations shift γ-secretase cleavage toward increased Amyloid beta (1-42), modeling mechanisms of familial Alzheimer’s disease. Neuroinflammation research: Applied to study microglial and astrocytic activation, cytokine release, and inflammatory responses induced by Amyloid beta aggregates that stimulate innate immune pathways. Seeding and cross-seeding studies: Used to examine how it acts as a nucleation seed for Aβ (1-40) fibrillization and how mixed Aβ species form distinct fibril structures in plaques. Comparison studies with Aβ (1-40): Used to compare aggregation kinetics, toxicity, structural stability, and diagnostic relevance with Beta amyloid (1-40).

Source: jpt.com ↗

What This Means for Researchers

This convergence of immunology and neuroscience is one of the most exciting fields of study right now. The similarities between LL-37 and Aβ open up entirely new avenues for therapeutic development and a deeper understanding of disease. Could we learn how to control pathological Aβ aggregation by studying how the body successfully regulates LL-37? Could modulating LL-37 levels or its activity be a novel therapeutic strategy for neuroinflammatory diseases? Answering these questions is a formidable challenge. It demands research materials of the highest possible quality. When you're investigating the subtle, concentration-dependent interactions between two peptides that can both help and harm, you simply cannot afford to have impurities or incorrect sequences in your samples. A tiny contaminant could skew aggregation kinetics or trigger an unintended inflammatory response, sending an entire research project down the wrong path. It's a difficult, often moving-target objective. That's the entire reason Real Peptides exists. Our commitment to small-batch synthesis and rigorous quality control ensures that the LL-37 and other compounds researchers use are exactly what they're supposed to be—pure, consistent, and reliable. This level of precision is a non-negotiable element for anyone working on the cutting edge. Our experience shows that breakthroughs are built on a foundation of trustworthy data, which starts with trustworthy reagents. This dedication to quality is something we apply across our full range of peptides. If your lab is ready to explore these complex biological questions, we're here to provide the high-purity tools you need to find clear answers. You can [Get Started Today] and see the difference that uncompromising quality makes. The story of LL-37 and Aβ is a potent reminder that biology doesn't operate in neat silos. The systems that protect us from microbes are deeply intertwined with the processes that can lead to chronic disease and aging. The villain may be a hero in a different context, and the hero's power, left unchecked, can cause its own form of damage. By understanding their surprising similarities, we're not just learning about two peptides; we're gaining a more profound insight into the delicate and often paradoxical nature of life itself.

Source: realpeptides.co ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →